CLDX
Price
$17.15
Change
-$0.23 (-1.32%)
Updated
Apr 3 closing price
Capitalization
1.14B
27 days until earnings call
RVPH
Price
$0.56
Change
-$0.00 (-0.00%)
Updated
Apr 3 closing price
Capitalization
26.16M
45 days until earnings call
Ad is loading...

CLDX vs RVPH

Header iconCLDX vs RVPH Comparison
Open Charts CLDX vs RVPHBanner chart's image
Celldex Therapeutics
Price$17.15
Change-$0.23 (-1.32%)
Volume$792K
Capitalization1.14B
Reviva Pharmaceuticals Holdings
Price$0.56
Change-$0.00 (-0.00%)
Volume$807.06K
Capitalization26.16M
CLDX vs RVPH Comparison Chart
Loading...
CLDX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RVPH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CLDX vs. RVPH commentary
Apr 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CLDX is a Hold and RVPH is a Buy.

Ad is loading...
COMPARISON
Comparison
Apr 04, 2025
Stock price -- (CLDX: $17.17 vs. RVPH: $0.56)
Brand notoriety: CLDX and RVPH are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CLDX: 101% vs. RVPH: 70%
Market capitalization -- CLDX: $1.14B vs. RVPH: $26.16M
CLDX [@Biotechnology] is valued at $1.14B. RVPH’s [@Biotechnology] market capitalization is $26.16M. The market cap for tickers in the [@Biotechnology] industry ranges from $299.64B to $0. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CLDX’s FA Score shows that 0 FA rating(s) are green whileRVPH’s FA Score has 1 green FA rating(s).

  • CLDX’s FA Score: 0 green, 5 red.
  • RVPH’s FA Score: 1 green, 4 red.
According to our system of comparison, RVPH is a better buy in the long-term than CLDX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CLDX’s TA Score shows that 4 TA indicator(s) are bullish while RVPH’s TA Score has 4 bullish TA indicator(s).

  • CLDX’s TA Score: 4 bullish, 4 bearish.
  • RVPH’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, both CLDX and RVPH are a good buy in the short-term.

Price Growth

CLDX (@Biotechnology) experienced а -14.06% price change this week, while RVPH (@Biotechnology) price change was -48.30% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -8.91%. For the same industry, the average monthly price growth was -11.19%, and the average quarterly price growth was -14.86%.

Reported Earning Dates

CLDX is expected to report earnings on May 01, 2025.

RVPH is expected to report earnings on May 19, 2025.

Industries' Descriptions

@Biotechnology (-8.91% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CLDX($1.14B) has a higher market cap than RVPH($26.2M). CLDX YTD gains are higher at: -32.133 vs. RVPH (-68.867). RVPH has higher annual earnings (EBITDA): -33.27M vs. CLDX (-191.9M). CLDX has more cash in the bank: 725M vs. RVPH (5.56M). RVPH has less debt than CLDX: RVPH (83K) vs CLDX (3.81M). CLDX has higher revenues than RVPH: CLDX (7.02M) vs RVPH (0).
CLDXRVPHCLDX / RVPH
Capitalization1.14B26.2M4,351%
EBITDA-191.9M-33.27M577%
Gain YTD-32.133-68.86747%
P/E RatioN/AN/A-
Revenue7.02M0-
Total Cash725M5.56M13,042%
Total Debt3.81M83K4,594%
FUNDAMENTALS RATINGS
CLDX vs RVPH: Fundamental Ratings
CLDX
RVPH
OUTLOOK RATING
1..100
6353
VALUATION
overvalued / fair valued / undervalued
1..100
57
Fair valued
91
Overvalued
PROFIT vs RISK RATING
1..100
64100
SMR RATING
1..100
96100
PRICE GROWTH RATING
1..100
8998
P/E GROWTH RATING
1..100
1009
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CLDX's Valuation (57) in the Biotechnology industry is somewhat better than the same rating for RVPH (91) in the null industry. This means that CLDX’s stock grew somewhat faster than RVPH’s over the last 12 months.

CLDX's Profit vs Risk Rating (64) in the Biotechnology industry is somewhat better than the same rating for RVPH (100) in the null industry. This means that CLDX’s stock grew somewhat faster than RVPH’s over the last 12 months.

CLDX's SMR Rating (96) in the Biotechnology industry is in the same range as RVPH (100) in the null industry. This means that CLDX’s stock grew similarly to RVPH’s over the last 12 months.

CLDX's Price Growth Rating (89) in the Biotechnology industry is in the same range as RVPH (98) in the null industry. This means that CLDX’s stock grew similarly to RVPH’s over the last 12 months.

RVPH's P/E Growth Rating (9) in the null industry is significantly better than the same rating for CLDX (100) in the Biotechnology industry. This means that RVPH’s stock grew significantly faster than CLDX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CLDXRVPH
RSI
ODDS (%)
Bullish Trend 1 day ago
83%
Bullish Trend 1 day ago
89%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 1 day ago
80%
Momentum
ODDS (%)
Bearish Trend 1 day ago
78%
Bearish Trend 1 day ago
82%
MACD
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 1 day ago
84%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
83%
Bearish Trend 1 day ago
83%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
83%
Bearish Trend 1 day ago
82%
Advances
ODDS (%)
Bullish Trend 24 days ago
84%
Bullish Trend 11 days ago
82%
Declines
ODDS (%)
Bearish Trend 4 days ago
80%
Bearish Trend 3 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
79%
Bullish Trend 1 day ago
80%
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
82%
View a ticker or compare two or three
Ad is loading...
CLDX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RVPH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
EKSO0.42N/A
+0.89%
Ekso Bionics Holdings
NCNO21.71-0.88
-3.90%
nCino
AFCG5.43-0.29
-5.07%
Advanced Flower Capital Inc
TRS22.35-1.22
-5.18%
TriMas Corp
EFX231.80-15.77
-6.37%
Equifax

CLDX and

Correlation & Price change

A.I.dvisor indicates that over the last year, CLDX has been loosely correlated with DNLI. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if CLDX jumps, then DNLI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CLDX
1D Price
Change %
CLDX100%
-1.32%
DNLI - CLDX
47%
Loosely correlated
-6.91%
ATXS - CLDX
45%
Loosely correlated
-6.70%
NTLA - CLDX
44%
Loosely correlated
-5.62%
KYMR - CLDX
44%
Loosely correlated
-10.13%
BEAM - CLDX
43%
Loosely correlated
-10.93%
More

RVPH and

Correlation & Price change

A.I.dvisor tells us that RVPH and GYRE have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that RVPH and GYRE's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RVPH
1D Price
Change %
RVPH100%
+0.32%
GYRE - RVPH
30%
Poorly correlated
-4.09%
TNYA - RVPH
25%
Poorly correlated
-8.11%
INM - RVPH
25%
Poorly correlated
+1.20%
CDIO - RVPH
24%
Poorly correlated
-4.44%
CLDX - RVPH
24%
Poorly correlated
-1.32%
More